Key result
S-61 and S-73 demonstrated potent prophylactic and therapeutic antiarrhythmic properties in adrenaline-induced arrhythmia models in rats, without proarrhythmic potential.
Why the study?
Available antiarrhythmic drugs show limited efficacy and proarrhythmic potential, prompting the search for safer and more effective therapies targeting α1-adrenoceptors.
Do S-61 and S-73 prevent or treat arrhythmia and lower blood pressure in rat models?
Do S-61 and S-73 prevent or treat arrhythmia and lower blood pressure in rat models?
S-61 and S-73, novel pyrrolidin-2-one derivatives with α1-adrenolytic properties, demonstrate promising antiarrhythmic and hypotensive effects in rat models without proarrhythmic risk.
Should not change clinical practice; leaves open translation of these rat-model effects to human arrhythmia therapy.
Heart rhythm abnormalities are a cause of many deaths worldwide. Unfortunately, the available antiarrhythmic drugs show limited efficacy and proarrhythmic potential. Thus, efforts should be made to search for new, more effective, and safer pharmacotherapies. Several studies suggested that blocking the α1-adrenoceptors could restore normal heart rhythm in arrhythmia. In this study, we aimed to assess the antiarrhythmic potential of S-61 and S-73, two novel pyrrolidin-2-one derivatives with high affinity for α1-adrenergic receptors. First, using radioligand binding studies, we demonstrated that S-61 and S-73 did not bind with β1-adrenoceptors. Next, we assessed whether S-61 and S-73 could protect rats against arrhythmia in adrenaline-, calcium chloride- and aconitine-induced arrhythmia models. Both compounds showed potent prophylactic antiarrhythmic properties in the adrenaline-induced arrhythmia model, but the effect of S-61 was more pronounced. None of the compounds displayed antiarrhythmic effects in calcium chloride- or aconitine-induced arrhythmia models. Interestingly, both derivatives revealed therapeutic antiarrhythmic activity in the adrenaline-induced arrhythmia, diminishing heart rhythm irregularities. Neither S-61 nor S-73 showed proarrhythmic potential in rats. Finally, the compounds decreased blood pressure in rodents. The hypotensive effects were not observed after coadministration with methoxamine, which suggests the α1-adrenolytic properties of both compounds. Our results confirm that pyrrolidin-2-one derivatives possess potent antiarrhythmic properties. Given the promising results of our experiments, further studies on pyrrolidin-2-one derivatives might result in the development of a new class of antiarrhythmic drugs.
No takes yet. Share an insight, caveat, or question.
Lustyk et al. (2022) studied Arrhythmia. S-61 and S-73 was evaluated on Antiarrhythmic properties in induced arrhythmia models. S-61 and S-73 demonstrated potent prophylactic and therapeutic antiarrhythmic properties in adrenaline-induced arrhythmia models in rats, without proarrhythmic potential.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: